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SUMMARY 
Proposed by Hales & Barker, the thrifty phenotype hypothesis explains how a change in 
fetal environment leading to fetal growth retardation, causes a permanent alteration in 
development of metabolic organs and their functions. These adaptions are necessary in 
order to survive and grow in a poor nutritional environment, but may cause metabolic 
diseases in later life if postnatal life is paradoxically characterized by having improved 
nutrition and catch-up growth.  
Although there are many studies in animal models showing associations between 
intrauterine growth restriction (IUGR) and the development of type 2 diabetes mellitus 
(T2DM), most studies have been done on the rodent model, which does not display 
similar reproductive physiology and disease progression as humans. Also, there is a lack 
of skeletal muscle tissues analysis of IUGR subjects in this field of research. A better 
animal model, such as the nonhuman primate model, is needed to reflect how the 
development of IUGR may later lead to T2DM in humans. Therefore, the aims of this 
thesis are to explore distinctive characteristics of insulin-glucose metabolism at the gene 
expression level, physical and biochemical characteristics in nutrition-mediated IUGR 
and impaired glucose tolerance (IGT) cynomolgus macaques. 
Studies on IUGR and IGT cynomolgus macaques were done concurrently. After a 35% 
high fat diet treatment, IGT macaques were heavier in weight, higher in body mass index,  
lower glucose clearance rate, hyperinsulinemia, and showed greater insulin resistance as 
compared to control macaques.  Gene expression analysis from real time polymerase 
chain reaction showed a 1.25-1.4 fold increase in AKT1, AKT2 and MSTN, and 2.3-2.8 
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fold decrease in IRS1 and SLC2A4RG in IGT macaques, indicating less responsive 
insulin-glucose signaling.  
IUGR macaques were weighed 10% lighter at birth and experienced a ‘catch-up growth’ 
in the first 3 months, before having similar growth patterns as control macaques till 9 
months. Higher glucose clearance rates, total cholesterol and triglycerides level were 
observed in IUGR macaques at 15 months. Furthermore, gene expression analysis 
showed a 3-6 fold decrease in AKT1, AKT2 and MSTN, and 1.9-7.7 fold increase in 
PIK3R1, IRS1 and SLC2A4RG, indicating accelerated glucose-insulin signaling. 
Subjected to high fat diet treatment, IUGR macaques exhibited similar characteristic as 
IGT macaques, having up regulated AKT1, MEF2A and GSK3b, and down regulated 
IRS1 compared to IUGR macaques undergoing a standard diet. Whereas, control 
macaques with high fat diet showed 1.8-4.7 fold increase in SLC2A4, HK2, IRS1 and 
SLC2A4RG, and 4 fold decrease in MSTN, indicating elevated insulin-glucose signaling. 
All these conclude that the insulin glucose metabolism in IUGR subjects were accelerated 
at the beginning and thus developed symptoms of IGT faster than normal subjects after 
being fed with a high fat diet.   
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CHAPTER 1 INTRODUCTION 
1.1 Intrauterine growth restriction  
Intrauterine growth restriction (IUGR) is a condition of poor fetal growth in utero, due to 
a maternal restricted environment in which a fetus is unable to achieve its maximum 
growth potential before it is born (Monk and Moore, 2004). Currently, the common 
markers used for detecting IUGR babies are the birth weight and the infant size relative 
to the population growth curves. Defined by World Health Organization (WHO), birth 
weight below 2500g and head/abdominal circumference below 10th percentile of the 
birth population are considered as ‘low birth weight (LBW)’ and ‘small for gestational 
age (SGA)’ respectively. A term baby born with LBW and SGA can be diagnosed as 
having IUGR (Harkness and Mari, 2004). IUGR can be subdivided into symmetric and 
asymmetric fetal growth. Head-to-abdominal circumference ratios (HC/AC) have been 
used at classifying fetuses into various subtypes based on head proportionality; overall 
smaller HC and AC with ratio close to normal baby morphometric (symmetrical) or those 
with relative head sparing (asymmetrical) (Harkness and Mari, 2004). Although the terms 
‘IUGR’, ‘LBW’ and ‘SGA’ have generally similar classification with one another, they 
are not interchangeable:  not all LBW or SGA babies are IUGR (Tan and Yeo, 2005). 
1.1.1 Implications of IUGR 
IUGR is one possible cause of adverse health effects in the later stages of an individual. 
Many epidemiological studies in human have uncovered associations between restricted 
growth in utero and the susceptibility to developing insulin resistance and/or impaired 
glucose tolerance (IGT) due to LBW, leading to the acquisition of chronic diseases such 
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as Type 2 diabetes mellitus (T2DM) and hyperlipidaemia in the later stages of life 
(Phillips et al, 1994; Eriksson et al, 2003; Gesina et al, 2004). These observations were 
explained using the “thrifty phenotype” hypothesis proposed by Hales & Barker, which 
states that fetal growth retardation causes a change in fetal environment, leading to a 
permanent alteration in development of metabolic organs and their functions, serving to 
protect key organs, especially the brain. Such fetal “programming” is necessary in order 
to survive and grow in a poor nutritional environment. However this may lead to 
metabolic diseases after having improved nutrition and catch-up growth later in life 
(Hales and Barker, 1992).   
1.2 Type 2 diabetes mellitus 
T2DM is one of the most common chronic diseases in the world. Until 2011, more than 
300 million people worldwide have been diagnosed with diabetes, of which 90% are 
classified as T2DM (WHO, 2001). This number is projected to double both by population 
size and mortality rates by the year 2030 (Wild et al, 2004). In Singapore, diabetes is the 
fifth most common medical condition diagnosed affecting more than 400,000 adults from 
18 to 65 years old. This number is about 11.3% of Singapore’s population. It is also one 
of the top 6 killer diseases in Singapore that have accounted for 1,700 to 3,500 deaths per 
annum from 2008 to 2010 (Ministry of Health, Singapore, 2011). Acquisition of T2DM is 
mainly due to lifestyle factors, and obesity is one of the factors strongly associated with 
T2DM (Weir and Leahy 1994). In Singapore, the prevalence of obesity in 2010 was 
10.8%. This is almost double the figure in 1998, where the prevalence was only 6.0% 
(Ministry of Health, Singapore, 2011), indicating a strong trend of growing numbers of 
T2DM patients in the future. High dietary fat diet, defined as diet with more than 30% of 
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calories derived from fat (Surwit et al, 1988), is one of the lifestyle factors that cause 
obesity. Foods which are high in fat content are commonly found in deep fried food, 
cream cakes, cookies, processed meat and canned food. Such diets are viewed as 
unhealthy as they increase the amount of fatty acids available for oxidation in skeletal 
muscle, resulting in excess energy available and causing energy imbalance in the body 
(Bray & Popkin, 1998). To deal with such problem, the body covert those excess energy 
to adipose tissues and distribute around organs and inside abdominal cavity for storage, 
causing obesity when excess body fats are accumulated.  
There are many long term complications that are associated with T2DM, and they are 
categorized into two groups: microvascular diseases (such as nephropathy, retinopathy 
and neuropathy) and macrovascular diseases (such as peripheral vascular disease, stroke, 
ischemic and coronary heart disease) (Betteridge, 1996; Coutinho et al, 1999; Sarwar et 
al, 2010; Boussageon et al, 2011) All these complications may lead to increased mortality, 
making T2DM a metabolic disease that cannot be neglected. 
1.2.1 Diagnosis of T2DM 
Singapore uses the same guidelines as WHO recommendations. T2DM can be diagnosed 
if any of the 3 following observations is presented: 
1. Fasting plasma glucose more than 7.0mmol/L 
2. Casual plasma glucose more than 11.1mmol/L 
3. 2 hours plasma glucose during 75g oral glucose tolerance test (OGTT) more than 
11.1mmol/L (Goh et al, 2011)  
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1.2.2 Progression of T2DM 
T2DM is a progressive disease that develops over the years with different stages: from 
normal glucose tolerance to an intermediate stage of IGT called prediabetes, and lastly 
aggravated to T2DM (Edelstein et al, 1997). T2DM is linked with a significant period of 
prediabetes characterized by increased basal insulin secretion, decreased insulin 
sensitivity and presence of insulin resistance (figure 1) (Cefalu WT, 2000; Barr et al, 
2007). Studies have showed that during this period of time, patients suffered a gradual 
drop in the insulin secretory capacity of pancreatic islet β-cell, causing IGT (Buchanaan 
2003; Weyer et al.1999, 2001).  
Using WHO and Singapore diagnostic criteria, IGT is diagnosed if fasting plasma 
glucose is between 6.1 to 7.0mmol/L or 2 hours plasma glucose during 75g OGTT 
between 7.8 to 11.1mmol/L (Goh et al, 2011). 
As the disease progresses, the islet function deteriorate to the point whereby it is unable 
to compensate fully for the degree of insulin resistance, clinically overt T2DM develops. 
(Buchanaan, 2003; Weyer et al.1999, 2001). Increased risk of hypertension, dyslipidemia, 
arteriosclerotic vascular disease and cardiovascular pathology were observed due to 
complications of abnormal glucose homeostasis (Cefalu WT, 2000; Barr et al, 2007). 
1.3 Insulin-glucose signaling pathway  
The insulin-glucose signaling system regulates the storage and usage of energy (primarily 
glucose), as well as the growth and development of tissue. Insulin plays a major role in 
blood glucose regulation as it promotes cellular glucose uptake, glycogen synthesis in 
skeletal muscle and liver, and inhibits gluconeogenesis in the liver (DeFronzo and 
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Ferrannini, 2001). It works in tandem with the glucose glycolysis pathway, utilizing this 
energy source to promote growth and development of tissue (DeFronzo and Ferrannini, 
2001).  
 
Figure 1: Progression of T2DM, highlighting the key metabolic syndrome in the genesis 
of the disease. The shaded area signifies the presence of the metabolic syndrome. 
Adopted from Cefalu WT, 2000. 
 
1.3.1 Overview of insulin action through IRS/PI3K/AKT pathway 
The overview of the insulin-glucose signaling pathway for glucose metabolism is shown 
in figure 2. At the start of the pathway, insulin binds to a cell surface receptor that 
belongs to a sub-family of growth factor receptor tyrosine kinases: Insulin receptor 
(INSR). INSR propagates the signal to insulin receptor substrate (IRS) by 
phosphorylation and then phosphatidylinositol 3-kinase (PI3K). PI3K activates a PI3K-
dependent kinases, PDPK1 (Alessi et al, 1997) which in turn phosphorylates and 
activates additional serine/threonine kinases, mainly AKT1 and AKT2 (Burgering and 
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Coffer, 1995). AKT phosphorylates glycogen synthase kinase 3 beta (GSK3b) (Cross et 
al, 1995), which removes the inhibition of glycogen synthase (GYS). Such action allows 
glycogenesis to proceed, converting excess glucose to glycogen for storage. AKT also 
phosphorylates and inhibits FOXO transcription factor Forkhead box O1 (FOXO1) 
(Brunet et al, 1999), leading to stimulation of glycolysis and gene expression for enzymes 
involving glycolysis, such as glucokinase (GCK), hexokinase (HK) and pyruvate kinase 
(PKM). 
In addition, there is evidence of AKT activation involved in stimulation of glucose 
transport via aiding the translocation of glucose transporter 4 (SLC2A4) (Kohn et al, 
1996). On the other hand, the expression of SLC2A4 is regulated by both Myocyte 
Enhancer Factor 2A (MEF2A) and glucose transporter 4 regulatory gene (SLC2A4RG). 
Both interact with each other to control the amount of SLC2A4 available for 
translocation to the cell membrane (Mora and Pessin, 2000; Sparling et al, 2008). 
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1.3.2 Abnormal gene regulation of insulin-glucose signaling pathway in T2DM 
There is evidence linking changes in expression profile of insulin-glucose gene with 
T2DM. Mice with IRS1 and IRS2 knockout exhibit insulin resistance and subsequently 
develop diabetes (Tamemoto et al, 1994; Araki et al, 1994). Reduced activation of PI3K 
due to decreased IRS1 signaling was observed in insulin resistant ob/ob mice and these 
observations were similar to streptozotocin induced diabetes rats (Folli et al, 1993). In 
addition, deletion of PI3K catalytic subunits alpha, beta, and regulatory subunit 1 in mice 
displayed IGT and hyperinsulinemia as compared to the control group (Brachmann et al, 
2004). Because of reduced IRS/PI3K activation, a decrease in PDPK1 activation was also 
seen in muscle tissue of human subjects suffering from T2DM (Kim et al, 1999). Another 
human muscle study showed that up regulated GSK3b activity was observed, which 
causes increased phosphorylation of GYS1 and deactivates glycogen synthase. The rate 
of glycogen synthesis was assessed after 75g OGTT and 3 hours hyperinsulinemic 
euglycemic clamps, whereby diabetes subjects had a slower rate of glycogen synthesis 
compared to normal subjects (Nikoulina et al, 2000). AKT phosphorylation was observed 
to be impaired in an in vitro insulin resistance muscle cell culture system, but this 
observation was not made in a muscle biopsy specimen (Ueki et al, 1998). Impaired 
activity and dysregulation of glycolytic enzymes HK, GCK and PKM were detected in 
patients with T2DM (Vestergaard et al, 1995; Njølstad et al, 2001; Wang et al 2002; 
Beale et al, 2004). Lastly, SLC2A4 and its gene regulation were affected in T2DM 
subjects. Impaired translocation of SLC2A4 to the cell membrane surface was reported in 
a study looking at insulin resistant human podocytes (Lennon et al, 2009). SLC2A4 
knockout mice developed severe insulin-resistant diabetes with high blood glucose 
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(Stenbit et al, 1997; Joost et al, 2002). Reduced MEF2A and/or SLC2A4RG decreases 
interaction at DNA binding site of the SLC2A4 gene and was discovered in diabetic mice 
(Mora and Pessin, 2000; Sparling et al, 2008). All the above indicates that any abnormal 
changes in this signaling pathway will result in insulin resistance, IGT and T2DM.     
1.3.3 Linking IUGR and T2DM 
Although there is significant evidence linking IUGR with the development of diabetes as 
each individual grows, the molecular mechanisms underlying the association between 
IUGR and the development of diabetes are not very well understood. Hence, there is an 
urgent need to understand the pathogenesis of T2DM caused by IUGR, in order to 
determine effective treatment and management of the disease. In order to investigate the 
molecular mechanisms by which IUGR leads to eventual development of T2DM, 
different animal models, mostly rodent models, have been developed and are widely used 
for such studies. There are four methods of generating IUGR animals: Bilateral uterine 
artery ligation, maternal low protein diet, maternal caloric restriction and over-exposure 
of the maternal glucocorticoid. Table 1 presents a meta-analysis of rodent models used 
for IUGR induction using the four methods mentioned, and their findings on the 
immediate and future impact on offspring. All, except the Vuguin et al study, showed 
significant lower birth in IUGR pups. Using birth weight as the main factor for successful 
IUGR induction, maternal caloric restriction appears as the best method out of the four 
mentioned. Islet and β-cell mass were smaller as compared to control pups, with 
decreased insulin secretion (Arantes et al, 2002; Styrud et al, 2005; Inoue et al, 2009). As 
for organs development, gene expression of key gluconeogenesis enzymes, 
phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase) and 
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peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) were up regulated 
in the liver of IUGR subjects (Nyirenda et al, 1998; Vuguin et al, 2004; Buhl et al, 2007; 
Liu et al, 2009). This phenomenon was explained by the failure to inhibit 
gluconeogenesis via AKT signaling pathway (Vuguin et al, 2004). Skeletal muscle 
research by Thamotharan et al discovered SLC2A4 expression level and protein were 
decreased in IUGR subjects (Thamotharan et al, 2004). As IUGR subjects grew up, they 
developed fasting hyperglycemia, hyperinsulinemia and IGT at the early stage of life, and 
then subsequently developed T2DM. The above mentioned data is summarized in figure 
3.  
 
Figure 3: Causes of IUGR, which have the impact on metabolic sites and develop T2DM 
in the later stage of life. Modification from Martin-Gronert and Ozanne, 2007. 
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1.4 Gaps in current research of IUGR and T2DM 
Although there are many studies in animal models showing associations between IUGR 
and the development of T2DM, most studies were done on the rodent model. Rodent 
models have obvious advantages such as ease of maintenance, short gestation periods, 
short lifespan, and most importantly lower cost, which makes longitudinal studies using 
large number of animals attractive. However a major limitation is that rodent model of 
diabetes does not demonstrate the similarities for pathophysiological conditions observed 
in humans with T2DM (Cefalu WT, 2006). In addition, most of the studies were focused 
on pancreas islet, β-cell and liver conditions in IUGR subjects, but only a handful of 
studies focused on skeletal muscle tissues of IUGR subjects. Being the main site of 
insulin-dependent glucose disposal, any abnormal condition or dysregulated gene 
detected at this area is an indication of the development of IGT and subsequently T2DM 
(Cline et al, 1999). Therefore, studies on this tissue are necessary to give a more 
comprehensive overview on the impact of growth restriction on the metabolic organs and 
the molecular pathogenesis of T2DM. Lastly, rodents have polytocous pregnancies and 
give birth to litters of offspring. Natural IUGR may arise from such pregnancies and will 
decrease the reliability of the study. Human pregnancies are generally monotocous. All 
these reasons suggest that there is a need for a better animal model reflecting the disease 
conditions in humans. 
1.5 Nonhuman primate: a better animal model of IUGR and T2DM 
There are many nonhuman primate models of diabetes in various existing studies. Old 
world nonhuman primates have reported natural cases of T2DM, with the disease starting
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Observations in IUGR subjects 






15%  Islet and β-
cell 
Mild fasting hyperglycemia and hyperinsulinemia 
observed. Became glucose intolerance, insulin-resistant 
and having 50% lesser in β-cells mass after 7 weeks 








Liver Basal hepatic glucose production was significantly 
higher in IUGR. PEPCK and G6Pase expression level 
was higher in IUGR 






10% Islet and β-
cell 
β-cell mass and insulin content were reduced by 35–40% 
in IUGR. No difference in glucose tolerant between 2 
groups initially, but IUGR were  glucose intolerant  after 
3 month 




10% Liver PEPCK and GR expression level was higher in IUGR. 
Fasting hyperglycemia, reactive hyperglycemia and 
hyperinsulinemia observed  






13%  Liver Fasting hyperglycemia and glucose intolerance observed. 
PEPCK and IGFBP-1 expression level was higher. No 
difference in  IGF-I and GR expression level 
Arantes et al., 
2002  
Wistar Low protein diet 
(6%) 
8% Islet and β-
cell 
IUGR have decrease in islet mass and insulin secretion. 
PDX-1 protein and mRNA levels were reduced in IUGR 
Liu et al., 2009  Wistar Low protein diet 
(8%) 
10% Liver Fasting hyperglycemia observed in IUGR. G6Pase, 
PEPCK,PGC-1α expression level was higher in IUGR 
Thamotharan 










No difference in SLC2A4 expression level in adipose 
tissue. Decrease SLC2A4 expression level in skeletal 
muscle was observed 





19% Islet and β-
cell 
75% decrease in β-cell mass and 60% decrease in islet 
density observed. Fasting hyperglycemia and glucose 
intolerance observed in IUGR. 
Table 1: Summary of studies using IUGR rodent model and exhibit changes in organs and gene involving in insulin-glucose 
metabolism.
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from glucose tolerance and insulin resistance with compensatory hyperinsulinemia, 
followed by IGT with declining glucose clearance, reported in k-value derived from 
intravenous glucose tolerance test (IVGTT), and lastly continued deterioration of insulin-
glucose prior to signs of hyperglycemia and diabetes (figure 4) (Hansen and Bodkin, 
1986; Bodkin, 2000; Wagner et al 2001; Tigno et al, 2004). T2DM prevalence increases 
in nonhuman primates with age and obesity (Bodkin, 2000). As the progressive history of 
the disease and the response to dietary management are closely similar to humans, therein 
lies the major advantage of disease detection as compared to rodent model whereby the 
prediabetic phase is often undetectable. Another advantage over the rodent model is the 
development of atherosclerosis in nonhuman primate models and increased risk of 
cardiovascular disease as T2DM progresses (Clarkson 1998), where these observations 
are not present in the rodent model. The nonhuman primate genome is genetically similar 
to the human genome, with the examples of the rhesus macaque (Macaca mulatta) and 
cynomolgus macaques (Macaca fascicularis) having 93% and 91% homology with 
humans respectively (Gibbs et al, 2007). Nonhuman primates are a better model for 
IUGR studies, as evidence shows similar reproduction physiology and in utero 
development of the fetus, especially endocrine development, compared to humans 
(Tarantal and Hendrickx, 1988). Furthermore, primates have monotocous pregnancies. 
The gestational period is shorter (154-180 days) compared to humans, though 
comparatively longer than rodent. However the high maintenance costs of nonhuman 
primate models may make them less attractive for longitudinal studies, explaining on the 
lack of longitudinal IUGR studies in nonhuman primate. Regardless, a longitudinal study 
on this area is highly beneficial, as any developments made through this nonhuman 
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primate study, enables a controlled study of the development of IUGR and later leading 
to T2DM in humans, and has potential for further studies in disease prevention. 
 
Figure 4: Progression of T2DM from lean to obese with IGT, hyperinsulinemia (HI), and 
T2DM in cynomolgus monkeys. The proposed association with cardiovascular disease 
(Vascular Dz) is projected. Adopted from Bodkin N.L, 2000. 
 
1.6 Hypotheses and objectives  
The proposed hypotheses in this thesis are:  
1. Metabolic gene expression levels, physical and biochemical characteristics are 
different in IUGR offspring displaying abnormal catch-up growth, as compared to 
normal offspring at the early juvenile stage of life   
2. Metabolic gene expression levels of genes involved in insulin and glucose 
metabolism, physical and biochemical characteristics are different between normal 
and IGT adult macaques  
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3. IUGR macaques with high fat diet develop IGT earlier than normal macaques, with 
the progression similar to the adult IGT macaques model  
From the hypotheses, the objectives derived are:  
1. To morphologically characterize nutrition-mediated IUGR infant cynomolgus 
macaques for the first 9 months of their life.  
2. To investigate the gene expression levels of genes involved in insulin and glucose 
metabolism, physical and biochemical characteristics, before and after high fat diet 
treatment in nutrition-mediated IUGR model. 
3. To establish an adult nonhuman primate IGT model using cynomolgus macaques  
4. To investigate the metabolic gene expression levels of genes involved in insulin and 
glucose metabolism, physical and biochemical characteristics in the adult IGT 
macaques model 
5. To explore any similarity in gene expression, physical and biochemical characteristics 
between IUGR macaques with high fat diet and the adult IGT macaques model. 
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CHAPTER 2  MATERIALS AND METHODS 
2.1 Cynomolgus macaque nutrition-mediated IUGR model 
Nutrition-mediated IUGR macaque model was set up by Chng et al (unpublished work) 
prior to my candidature. The study is as follows: sexually mature male and female 
cynomolgus macaques were group housed for natural breeding. Female macaques were 
routinely scanned by ultrasound (GE Logiq S6, GE Healthcare) every three weeks to 
facilitate pregnancy detection. Once pregnancy was confirmed, macaques were randomly 
assigned to either the control or IUGR group. Control dams were given 100% standard 
lab diet (Laboratory Fiber-Plus Monkey Diet 5049, Lab Diet) throughout the pregnancy, 
whereas IUGR dams were given 35% fewer in amount compared to the control dams 
from Gestational day (GD) 32 to GD 70, and then 30% fewer in amount from GD 71 to 
the end of pregnancy. All food intake were monitored throughout pregnancy and 
pregnant dams were scanned every month from GD 30 to GD 125 to monitor fetal 
viability and growth in utero. All neonates were delivered naturally and their birth 
weights and morphometrics were measured at birth.  
The growth of macaques derived from the control and IUGR group were monitored 
throughout the study. Weight and morphometrics were measured every three months 
staring from birth. IVGTT and blood test were done at 12 months of age. All were given 
100% standard lab diet, until 15 months where diet treatment was started, and macaques 
were further divided randomly into four groups: Control-Standard diet (C-S), Control-
High fat diet (C-H), IUGR-Standard diet (I-S), IUGR-High fat diet (I-H). Standard diet 
groups continued to receive standard lab diet (Laboratory Fiber-Plus Monkey Diet 5049, 
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Lab Diet) comprising 26% protein, 14% fat and 60% carbohydrate. However, high fat 
diet groups were given 35% high fat diet (Obesity induced primate diet, Altromin) 
comprising 18% protein, 35% fat and 47% carbohydrate. Weight, physical measurement, 
IVGTT and blood tests and muscle biopsies were carried out at 15 months (before diet 
treatment) and 24 months (9 months after diet treatment)  
All animal procedures were approved and conducted in compliance with standards of 
Agri-Food & Veterinary Authority of Singapore, and guidelines established by the 
Institutional Animal Care and Use Committee of Singapore Health Services, under 
protocol IACUC #2009/SHS/445. Animal husbandry and veterinary procedures were 
done with the assistance of research veterinarian and technicians. The studies in this 
thesis started when most of the juvenile macaques were at 18 months old. 
2.2 Adult cynomolgus macaque IGT model 
14 male macaques were randomized into two groups, NGT (Normal glucose tolerance) 
and IGT (Impaired glucose tolerance). NGT group was given the standard lab diet 
(Laboratory Fiber-Plus Monkey Diet 5049, Lab Diet), while the IGT group was given 
high fat diet (Obesity induced primate diet, Altromin). Muscle biopsy, IVGTT, blood test 
and morphometric measurements were scheduled 6 months after diet treatment. All 
animal procedures were approved and conducted in compliance with standards of Agri-
Food & Veterinary Authority of Singapore, and guidelines established by the Institutional 
Animal Care and Use Committee of Singapore Health Services, under protocol IACUC 
#2008/SHS/418. 
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2.3 IVGTT, blood test and physical measurement 
Each subject was fasted overnight for at least 16 hours prior to an IVGTT. On the day of 
the procedure, the subject was sedated with 10mg/kg ketamine hydrochloride (Parnell) 
intramuscularly. After the subject was anesthetized, it was weighed and transferred to 
procedure table. A total of 3 ml of blood was drawn and the tubes were centrifuged at 
3,000 relative centrifugal force (rcf) for 10 minutes at room temperature. The blood 
serum was transferred into new tubes and they were sent to NUS referral laboratory for 
glucose, insulin and lipid panel analysis. 
IVGTT was performed after blood taking. Fasting glucose (t = 0 minute) was measured 
using a handheld glucometer (Medisense Optium Xceed, Abbott Singapore), before 
injecting 750mg/kg dextrose mixed with an equal volume of saline (0.9% sodium 
chloride) intravenously over 3 minutes. Glucose was measured at 9 different time points 
(t = 1, 5, 7, 10, 15, 20, 30, 40, 60 minutes) after dextrose injection. One final 
measurement at t = 90 minutes was taken to ensure that blood glucose had returned to 
normal levels, additional measurements were taken every 10 minutes if blood glucose 
was still above the normal range.  
Subject’s weight, crown-rump length (CRL) and crown-heel length (CHL) were taken 
prior to transport back to the cage. The k-value from the IVGTT data was calculated 
using the formula proposed by Dreval and Ametov, 2007. Body mass index (BMI) for 
adult macaques were calculated using the formula: 
           
        
  or  
           
        
. With the 
fasting glucose and insulin obtained, homeostasis model assessment of insulin resistance 
(HOMA-IR) was calculated using formula written by Matthew et al, 1985, and 
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Quantitative insulin sensitivity check index (QUICKI) was calculated using formula 
written by Katz et al, 2000. All values were recorded in the subject file and kept for 
further analysis. 
2.4 Muscle biopsy 
Subject was fasted overnight at least 16 hours prior to the procedure. On the day of the 
biopsy, the subject was sedated with 10mg/kg ketamine hydrochloride (Parnell) 
intramuscularly. After the subject was anesthetized, it was weighed and transferred to a 
procedure table. The hair at the right lateral thigh was shaved to expose the skin. Using 
the thigh-pelvis joint as a reference point, appropriately 3cm to the left of greater 
trochanter of femur was marked for site of biopsy (figure 5). The area was disinfected 
using hexodane and septanol (ICM Pharma) followed by punching the area using a sterile 
6mm biopsy punch (Stiefel). Immediately, the tissue extracted was trimmed and weighed,  
 
Figure 5: Muscle biopsy of cynomolgus macaques indicating the position of thigh-pelvis 
joint and the site of muscle to be taken.  
thigh-pelvis joint 
~ 3cm 
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and the muscle tissue was transferred into a cryovial, which was snap frozen in liquid 
nitrogen. At the same time, the excision area was sutured and cleaned, followed by 
administration of subcutaneous analgesic and antibiotic (1.4mg/kg Carpofen and 
75mg/kg Betamox respectively). The subject was returned to the cage and placed under 
observation for a few days. All tissues were stored at -80
o
C until further processing 
2.5 Oligonucleotide primers design and production  
Oligonucleotide primers were designed using the web-based program NCBI primer 
BLAST (www.ncbi.nlm.nih.gov/tools/primer-blast) and primer3 (frodo.wi.mit.edu). As 
cynomolgus macaque genome was not yet available at that point of time, human and 
rhesus macaque genome were used for the primer design and sequence alignment was 
done to confirm that flanking regions were conserved. Desired primers were ordered 
from Sigma and resuspended in 100ul of Milli-Q water (Merck Millipore). Working 
primer solutions were prepared by diluting the stock to 2uM with Milli-Q water. All 
primers were stored at -20
o
C. The primers used are listed in table 2. 
2.6 Total RNA extraction 
1ml of TRIzol (Invitrogen) was added into each muscle tissue sample, followed by 
samples homogenization using gentleMAC Dissociator and M-tube (Miltenyi Biotec) 
with the following manufacturer settings shown in table 3. After homogenization, the 
tubes were centrifuged at 3,000 rcf for 5 minutes at 4
o
C, transferring the supernatant to a 





C) for 5 minutes, before adding 200ml chloroform (Sigma) to 
each tube, then vortexing them for 15 seconds and incubating for another 3 minutes
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Gene code Gene name 
Function 
Primer Sequence (5’ to 3’)  
Product 
size (bp) 
SLC2A4 Glucose transporter 4 
Transportation of 
glucose across cell 



















Insulin receptor substrate 
2 







Myocyte enhancer factor 
2A 
transcription factor for  












GYS1 Glycogen synthase 1 





HK2 Hexokinase 2 
phosphorylation 






v-akt murine thymoma 
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AKT2 
v-akt murine thymoma 

























































Glycogen synthase kinase 
3 beta 
phosphorylation and 





FOXO1 Forkhead box O1 
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IRS1 
Insulin receptor substrate 
1 







Glucose transporter 4 
regulatory gene 
Regulation of 
SLC2A4 gene and 
















BACT Beta actin 
Cell cytoskeleton 
(Housekeeping gene 




RPL13A Ribosomal protein L13a 
Component of 
ribosomes for protein 
systhesis 
(Housekeeping gene 
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Step no Speed Direction Duration 
1 4000 rpm clockwise 10 seconds 
2 3700 rpm anticlockwise 8 seconds 
3 2300 rpm clockwise 10 seconds 
4 3400 rpm clockwise 7 seconds 
5 2600 rpm anticlockwise 10 seconds 
6 3400 rpm clockwise 10 seconds 
Table 3: Details of gentleMAC Dissociator setting for samples homogenization. 
at room temperature. The microtubes were further centrifuged at 12,000 rcf for 15 
minutes at 4
o
C. After centrifugation, 3 phases were visible in the microtubes: aqueous 
upper phase containing RNA, white interphase containing DNA and red lower phase 
containing protein. The aqueous phase was carefully removed and transferred into a new 
2ml microtube. Total RNA was precipitated by adding 525ul of Isopropanol (Sigma) to 
each microtube and inverting them several times before incubating them for 15 minutes 
at room temperature. Next, the microtubes were centrifuged at 12,000 rcf for 10 minutes 
at 4
o
C, then removing the supernatant and collect the RNA pellet. The RNA pellets were 
resuspended in 87.5ul of molecular grade water (First Base Pte Ltd). 
2.7 DNase I digestion 
DNase I was prepared by mixing 2.5ul of DNase I stock solution (Qiagen) with 10ul of 
buffer RDD (Qiagen) for each reaction. The 12.5ul working DNase I was added to 87.5ul 
of RNA and incubated at room temperature for 20 minutes. Lastly, the digestion was 
stopped by incubating the solution at 70
o
C for 10 minutes.  
2.8 RNA purification  
RNA purification was done using Qiagen RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol. 
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With the 100ul DNase I digested RNA solution, 350ul of Buffer RLT was added, 
followed by adding 250ul of 100% ethanol (Sigma). The entire volume was transferred to 
a RNeasy spin column and centrifuged at 12,000 rcf at room temperature for 1 minute. 
The flow through was discarded, 500ul Buffer RPE was added to the spin column and 
centrifuged at 12,000 rcf at room temperature for 1 minute. The previous step was 
repeated with a longer centrifugation time of 5 minutes.  Subsequently, the column was 
placed in a new 1.5ml microtube, 30ul of DEPC water was added to the spin column and 
incubated at room temperature for 2 minutes. The spin column was centrifuged at 12,000 
rcf for 5 minute at room temperature. Finally, the column was discarded and the 
microtube containing purified RNA was kept at -80
o
C for storage.  
2.9 RNA quantification  
All RNA was quantified using a Nanodrop ND-8000 spectrophotometer (Thermo Fisher 
Scientific). 1ul of the RNA was pipetted onto the detector and the absorbance at 230, 260 
and 280nm was read. All the values from the readings were used to determine the purity 
and quantity of RNA in the sample. 
2.10 RNA integrity assay 
The integrity of total RNA extracted was analyzed using Agilent 2100 Bioanalyzer and 
Agilent RNA 6000 Nano Kit (Agilent Technologies) according to the manufacturer’s 
protocol. RNA 6000 Nano dye concentrate was placed on the work bench to equilibrate 
to room temperature for 30 minutes. Next, 550ul of RNA 6000 Nano gel matrix was 
pipetted into a spin filter and centrifuged at 1,500 rcf for 10 minutes at room temperature. 
65ul of the filtered gel was aliquoted into a new 1.5ml microtube and 1ul of RNA 6000 
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Pico dye concentrate was added. The mixture was vortexed for 10 seconds, followed by 
centrifuging at 13,000 rcf for 10 minutes at room temperature. The gel-dye mix was 
added to RNA 6000 nano chip and the chip was primed using the chip priming station, 
before adding 1ul of heat denatured (70
o
C for 2 minutes) RNA samples and RNA 6000 
Nano ladder, both mixed with 5ul of RNA 6000 nano maker, into the primed chip. The 
chip was vortexed at 2400 rpm for 1 minutes using IKA vortexer (IKA laboratory 
technology). Lastly the chip was inserted into Agilent 2100 bioanalyzer and the setup was 
run according to the default program setting. RNA with RNA integrity number (RIN) of 
more than 5.0 was deemed acceptable and suitable for gene quantification using real time 
Polymerase Chain Reaction (PCR) as recommended by the manufacturer protocol. 
2.11 First strand cDNA synthesis  
cDNA was synthesized using Applied Biosystems High-capacity cDNA Reverse 
Transcription Kits (Applied Biosystems) according to the manufacturer’s protocol. 1ug of 
total RNA was added to a reaction mix containing 5.8ul of 10x RT buffer, 100mM dNTP, 
10x RT random primers and 50 U/ul MultiScribe Reverse Transcriptase. The solution 
was adjusted to 20ul with molecular grade water, giving a final working solution of 1 ug 
RNA, 1x RT buffer and random primers, 4mM dNTP and 25U reverse transcriptase. The 
reactions were incubated at 25
o
C for 10 minutes, then 37
o
C for 120 minutes and lastly 
85
o
C for 5 minutes. All cDNA was stored at -20
o
C 
2.12 Real time PCR  
Real time PCR was performed using Power SYBR Green PCR Master Mix (Applied 
Biosystems). 20ng of cDNA was added to a reaction mix containing 12ul of 2x PCR 
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master mix and 2uM of both forward and reverse primers. The solution was adjusted to 
20ul with molecular grade water, giving a final working solution of 20ng cDNA, 1x PCR 
master mix, 100nM forward and reverse primers. Reactions were pipetted on a 384-well 
plate and the plate was inserted into 7900HT Fast Real-Time PCR System (Applied 
Biosystems) with the following setting in SDS 2.3 shown in table 4. 
Gene of interest PCR Process Temperature Duration Cycle 
SLC2A4, INSR, GCK, 
IRS2, MEF2A,PKM2, 
GYS1, HK2, AKT1, 
AKT2, MSTN, PIK3Ca, 
PIK3Cb, PIK3R1, 
PDPK1, GSK3b, FOXO1, 





C 10 minutes 1 
Denaturation 95
o











C 10 minutes 1 
Denaturation 95
o





C 60 seconds 
Table 4: Details of real time PCR setting for different gene of interest. 
 





C at 0.2% increment speed over 15 minutes. The PCR products were run on a 1.5% 
agarose gel and stained with ethidium bromide.  
2.13 Gel extraction and sequencing 
Selected PCR products (INSR, SLC2A4, IRS1, IRS2, PKM2, GCK, GYS1, MEF2A, 
GAPDH) were extracted from agarose gel and purified using BMIAquick Gel Extraction 
Kit (Qiagen) according to the manufacturer’s protocol. Gel slice with DNA fragment was 
trimmed to 200mg and transferred into a 2ml microtube containing 600ul of Buffer QG. 
The microtube was incubated at 50
o
C for 10 minutes with vortexing every 2 minutes 
during the incubation. Next, 100ul of isopropanol was added to the microtube and the 
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whole volume was transferred to the BMIAquick column before centrifuging at 13,000 
rcf for 1 minute at room temperature. The flow-through was discarded and 0.5ml of 
Buffer QG was added to the column, followed by centrifuging at 13,000 rcf for 1 minute 
at room temperature. Once again, the flow-through was discarded. After that, 0.75ml of 
Buffer PE was added to the column and centrifuged at 13,000 rcf for 1 minute at room 
temperature. Additional 1 minute of centrifugation at 17,900 rcf was done after the flow-
through was discarded. The column was placed into a clean 1.5ml microtube and 50ul of 
Buffer EB was added to the center of the column. The column was allowed to stand for 1 
minute, before centrifuging at 13,000 rcf for 1 minute at room temperature to elute the 
DNA fragment.  
Purified PCR products were sent to First Base Pte Ltd, Singapore, for sequencing. 
Sequences received were analyzed and aligned against Human and Rhesus macaque 
genome using ClustalW2. Also, sequences were aligned against cynomolgus macaque 
genome using web-based program NCBI BLAST. 
2.14 Real time PCR analysis 
SDS v2.3 software was used to determine the Ct value of all reactions. Ct value of all 
genes had been normalized against the geometric mean of three housekeeping genes, 
GAPDH, BACT and RPL13a, to generate the Δct value for all genes expression for each 
macaque. Group Δct was calculated by taking the average Δct of each individual 
macaque gene expression. Using the comparative CT method, relative quantification (RQ, 
2
-ΔΔct
) of each gene expression level was determined using the NGT group as a reference 
group. 
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2.15 Statistical analysis 
All statistical analysis was carried out using SPSS 19.0 software package (IBM). 
Independent student’s t-tests, one-way analysis of variance (ANOVA) and Pearson 
product-moment correlation coefficient were used for parametric data analysis and. 
Mann–Whitney U test, Kruskal-Wallis one-way ANOVA and Spearman's rank 
correlation coefficient were used on non-parametric data analysis. All descriptive statistic 
will be presented in mean (standard deviation, SD), except for data that were highly 
skewed, in which median (minimum-maximum) will be reported instead. All probability 
values were 2-tailed, and p value less than or equal to 0.05 was considered statistically 
significant for all tests. 
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CHAPTER 3 RESULTS 
3.1 Primer efficiency and specificity 
Primer efficiency tests were done by performing real time PCR with four DNA templates 
of different concentration (1.0, 0.1, 0.01, 0.001 ng). Figure 6 shows the standard curve of 
FOXO1 PCR. Using the formula:               
  
             , primer for 
FOXO1 has 100% efficiency. Calculation of all primer efficiency displayed at least 90% 
efficiency in all reactions (figure 7). Therefore the comparative CT method can be 
deployed to calculate ΔΔct, RQ and fold change of the expression of genes of interest.    
 
Figure 6: Standard curve of FOXO1 Real time PCR for primer efficiency calculation. 
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Figure 7: PCR efficiency of all the primers used in the experiments. 
 
All primers designed were tested and optimized on adult cynomolgus macaque’s muscle 
cDNA. Figure 8 shows an agarose gel electrophoresis of the PCR products using primers 
listed in table 2. All primers yielded only one product of the intended size. Dissociation 
curve analysis supported the agarose gel electrophoresis result by showing one peak for 
all reactions (figure 9). Sequencing results for selected PCR products confirmed the 
specificity of the primers, as ClustalW2 showed at least 95% and 98% homology against 
human and rhesus macaque sequences respectively (table 5). With the cynomolgus 
macaque genome available recently, primers and PCR sequences were aligned against 
them using web-based program NCBI BLAST. The BLAST results showed the primer 
sequence have at least 90% homology with cynomolgus macaque genome, and the PCR 
sequences have at least 95% homology with the expected value not more than 0.0001. 
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Figure 8: 1.5% Agarose gel electrophoresis of PCR products. Top from left: 100bp 
marker, SLC2A4, INSR,AKT1,AKT2,MEF2A,GYS1,MSTN,PIK3Ca, PIK3Cb, PIK2R1, 
PDPK1, GSK3b. Bottom from left: 100bp marker, FOXO1,HK2, GCK, PKM2, 




% homology against 
Human 
% homology against 
Rhesus macaque 
INSR 97% 99% 
SLC2A4 95% 99% 
IRS1 98% 98% 
IRS2 96% 98% 
PKM2 98% 99% 
GCK 97% 99% 
GYS1 95% 99% 
MEF2A 98% 99% 
GAPDH 96% 99% 
Table 5: Sequence homology of PCR products against human and rhesus macaque 
sequences derived from multiple sequence alignment using ClustalW2 
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Figure 9: Dissociation curve analysis of PCR products. A: SLC2A4, B: AKT2, C: 
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3.2 Cynomolgus macaque nutrition-restricted IUGR model 
3.2.1 Morphometric analysis: juvenile macaques from 0 to 9 months  
Table 6 to 9 summarizes the juvenile macaques’ morphometric at 0 month, 3 months, 6 
months and 9 months treatment. Mann-Whitney U test was used for statistical analysis to 
access any differences between control and IUGR cohort. Macaques that were born less 
than 154 days of gestational period were not included in this study as they were 
considered premature neonates.  
From the results, the IUGR cohort were 10% lighter than the control cohort at birth and 
this difference in birth weight was significant (Z = -1.981, p = 0.048). After 3 months, the 
two groups had similar weights (±1%) and this observation persisted throughout till they 
were nine months old. For CRL and BMI, there were no significant differences observed 
from birth to 9 months old.  
Physical 
morphometric 
at birth  
(0 month) 
Control cohort 
(n = 24) 
IUGR cohort 
(n = 12) 
Mann–Whitney U test  
(2-tailed) 
U Z p  
Weight (g) 323 (39.0) 291 (43.2) 86 -1.981 0.048 
CRL (cm) 14.0 (1.49) 14.1 (1.67) 141 -0.103 0.918 
BMI (kg/m
2
) 16.9 (2.91) 15.1 (3.85) 114 -1.007 0.132 
Table 6: Neonates’ morphometric at birth. Values presented are in the format of mean 




at 3 months 
old 
Control cohort 
(n = 24) 
IUGR cohort 
(n = 12) 
Mann–Whitney U test  
(2-tailed) 
U Z p  
Weight (g) 653 (101.8) 655 (61.2) 133 -0.352 0.724 
CRL (cm) 20.1 (1.95) 19.3 (1.62) 115 -0.976 0.329 
BMI (kg/m
2
) 16.3 (3.16) 18.0 (3.55) 112 -1.074 0.283 
Table 7: infant macaques’ morphometric at 3 months old. Values presented are in the 
format of mean (SD).  





at 6 months 
old 
Control cohort 
(n = 24) 
IUGR cohort 
(n = 12) 
Mann–Whitney U test  
(2-tailed) 
U Z p  
Weight (g) 976 (113) 965 (104) 143 -0.034 0.973 
CRL (cm) 23.2 (1.77) 23.7 (2.13) 144 -1.008 0.313 
BMI (kg/m
2
) 18.2 (2.74) 17.1 (2.69) 114 -1.007 0.314 
Table 8: Juvenile macaques’ morphometric at 6 months old. Values presented are in the 









(n = 24) 
IUGR cohort 
(n = 12) 
Mann–Whitney U test  
(2-tailed) 
U Z p  
Weight (g) 1178 (101) 1165 (113) 115 -0.195 0.846 
CRL (cm) 25.8 (1.76) 25.6 (2.13) 114 -0.234 0.815 
BMI (kg/m
2
) 17.9 (2.19) 18.1 (3.27) 108 -0.467 0.640 
Table 9: Juvenile macaques’ morphometric at 9 months old. Values presented are in the 
format of mean (SD).  
 
The differences in weight, CRL and BMI between 0 to 3 months, 3 to 6 months and 6 to 
9 months were calculated to determine if there were any significant fluctuations during 
those three months period. Again, Mann-Whitney U test was used for such assessment. It 
was noticed that IUGR cohort gained more weight from 0 to 3 months as compared to 
control cohort. However, this result was not significant (p > 0.05). Weight gained from 3 
to 6 months and 6 to 9 months were similar for both cohorts (figure 10). For the length of 
the body (CRL), IUGR cohort grew slower from 0 to 3 month, but the growth accelerated 
during 3 to 6 months as compared to control cohort. All these observations were not 
significant (p > 0.05). Growth in body length was similar for both cohorts from 6 to 9 
months (figure 11).  
Interestingly, IUGR cohort had a 19% increase in BMI from 0 to 3 months. This increase 
was significant as compared to the change in BMI for control cohort, in which there was 
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a slightly decrease in BMI from 0 to 3 months (Z = -2.05, p = 0.040).  Fluctuations in 
BMI continued from 3 to 6 months and 6 to 9 months (figure 12), but such fluctuations 
observed were not significant (p > 0.05). Eventually, BMI stabilized at the 9 month old 
point whereby both cohorts had similar BMI. 
3.2.2 IVGTT analysis: juvenile macaques at 12 months  
16 control juvenile macaques and 12 IUGR juvenile macaques had undergone IVGTT 
and the rate of glucose clearance (k-value) was calculated. Mann-Whitney U test was 
used to determine any significant differences. It was found that IUGR juvenile macaques 
were 19% higher in the rate of glucose clearance as compared to the control cohort, 
however this difference observed was not significant (Z = -1.811, p = 0.070). There were 
no differences in their weight, CRL and IQ for both cohorts at 12 months old (table 10). 
 
Figure 10: Trend of juvenile macaques’ weight and weight gains from 0 to 9 months. 
Error bars denote SD. Numbers in blue and red show the average weight of control 
juvenile macaques and IUGR juvenile macaques respectively. Numbers in bracket show 
the weight gain between 2 periods. * indicates p < 0.05 
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Figure 11: Trend of juvenile macaques’ CRL and CRL gains from 0 to 9 months. Error 
bars denote SD. Numbers in blue and red show the average weight of control juvenile 
macaques and IUGR juvenile macaques respectively. Numbers in bracket show the CRL 
gain between 2 periods.  
 
Figure 12: Trend of juvenile macaques’ BMI and BMI changes from 0 to 9 months. Error 
bars denote SD. Numbers in blue and red show the average weight of control juvenile 
macaques and IUGR juvenile macaques respectively. Numbers in bracket show the BMI 
gain/loss between 2 periods. * indicates p < 0.05 
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Parameters at 
12 months old 
Control cohort 
(n = 16) 
IUGR cohort 
(n = 12) 
Mann–Whitney U test  
(2-tailed) 
U Z p  
Weight (kg) 1.31 (0.13) 1.26 (0.17) 81 -0.697 0.486 
CRL (cm) 27.3 (1.00) 26.5 (1.81) 69 -1.262 0.207 
BMI (kg/m
2
) 17.6 (1.91) 17.9 (1.84) 92 -0.186 0.853 
IVGTT 
k-value 
4.17 (2.21) 4.95 (1.38) 57 -1.811 0.070 
Table 10: Juvenile macaques’ morphometric and IVGTT k-value at 12 months old. 
Values presented are in the format of mean (SD). 
 
3.2.3 Physical and biochemical properties analysis: juvenile macaques at 15 months  
For 15 months analysis, only the data of 6 control juvenile macaques and 2 IUGR 
juvenile macaques were valid and analyzed. As the distribution of this set of data is 
highly skewed, median and range were reported instead. Mann–Whitney U test was 
deployed to access any differences between the two groups. From the results shown in 
table 11, IUGR juvenile macaques had a higher glucose clearance, total cholesterol and 
triglycerides. The differences observed were significant (p < 0.05). There were no 
significant differences in weight, CRL, BMI, fasting glucose and insulin, HDL, LDL, 
insulin resistance and sensitively indexes (p > 0.05). 
3.2.4 Metabolic gene expression analysis: juvenile macaques at 15 months  
RNA extracted from 8 muscle tissues achieved RIN of 6.2 to 7.8, confirming their 
suitability for cDNA synthesis and real time PCR analysis. During the calculation of the 
gene expression analysis shown in table 12 and figure 13, normalization against the 
geometric mean of three housekeeping genes, GAPDH, BACT and RPL13a, were done 
and relative quantification of each gene expression level was calculated using control 
group as reference group. Mann–Whitney U test was used to check any significant 
differences in the regulation observed. 
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parameters at 15 
months old 
Control cohort 
(n = 6) 
IUGR cohort 
(n = 2) 
Mann–Whitney U test  
(2-tailed) 
U Z p  
Weight (Kg) 1.30 (1.13-1.42) 1.41 (1.26-1.56) 4.0 -0.67 0.505 
CRL (cm) 26.4 (25.0-27.3) 26.7 (24.8-28.5) 6.0 0.00 1.000 
BMI (kg/m
2
) 18.9 (17.3-19.8) 19.8 (19.2-20.4) 3.0 -1.00 0.317 
IVGTT 
k-value 
3.46 (0.73-4.43) 6.01 (5.73-6.29) 0.0 -2.00 0.046 
Fasting glucose 
(mmol/L) 
3.00 (2.10-5.70) 2.60 (2.40-2.80) 3.0 -1.03 0.306 
Fasting insulin 
(mU/L) 
8.45 (6.80-48.3) 7.75 (7.70-7.80) 4.0 -0.67 0.505 
Total cholesterol 
(mmol/L) 
2.77 (2.09-3.51) 4.52 (3.72-5.31) 0.0 -2.00 0.046 
Triglycerides 
(mmol/L) 
0.40 (0.38-0.53) 0.90 (0.57-1.22) 0.0 -2.01 0.044 
HDL (mmol/L) 1.08 (0.69-1.91) 1.28 (0.26-2.29) 6.0 0.00 1.000 
LDL (mmol/L) 1.32 (1.04-2.12) 1.59 (0.70-2.47) 6.0 0.00 1.000 
HOMA-IR 1.15 (0.66-12.2) 0.90 (0.83-0.96) 2.0 -1.33 0.182 
QUICKI 0.37 (0.27-0.41) 0.39 (0.39-0.40) 2.0 -1.33 0.182 
Table 11: Juvenile macaques’ morphometric and biochemical parameters at 15 months 
old. Values presented are in the format of median (min-max). Highlighted rows indicate p 
< 0.05 
 
From the results, 11 genes were down regulated in IUGR juvenile macaques, with 6 
genes having more than 2 to 6 fold decrease in expression level. However, only AKT2, 
which was decreased about 6 fold in expression level in IUGR, was found to be 
significant (U = 0.0, Z = -2.0, p = 0.046). 7 genes were found to be up regulated with a 
magnitude of 1.4 to 7.6 fold. Out of the 7 genes, 3 genes were found to be significantly 
up regulated: PIK3R1 (1.9 fold increase, U = 0.0, Z = -2.0, p = 0.046), IRS1 (5.4 fold 
increase, U = 0.0, Z = -2.0, p = 0.046) and SLC2A4RG (7.6 fold increase, U = 0.0, Z = -
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Gene Relative quantification of IUGR group 
(control group as reference) 
Mann–Whitney U test  
(2-tailed) 
Magnitude Direction  U  
 
Z p  
SLC2A4 3.73 x Down regulated 3.0 -1.00 0.317 
INSR 1.08 x No Change 5.0 -0.33 0.739 
GCK 1.49 x Down regulated 5.0 -0.33 0.739 
IRS2 2.68 x Up regulated 3.0 -1.00 0.317 
MEF2A 3.33 x Down regulated 1.0 -1.67 0.096 
PKM2 1.17 x Down regulated 6.0 0.00 1.000 
GYS1 5.31 x Down regulated 2.0 -1.33 0.182 
HK2 1.08 x No Change 5.0 -0.33 0.739 
AKT1 3.05 x Down regulated 1.0 -1.00 0.317 
AKT2 5.96 x Down regulated 0.0 -2.00 0.046 
MSTN 6.01 x Down regulated 1.0 -1.67 0.096 
PIK3Ca 1.47 x Up regulated 0.0 -1.00 0.317 
PIK3Cb 1.44 x Up regulated 3.0 -1.33 0.182 
PIK3R1 1.90 x Up regulated 4.0 -2.00 0.046 
PDPK1 1.66 x Down regulated 3.0 -1.00 0.317 
GSK3b 2.05 x Up regulated 4.0 -0.67 0.505 
FOXO1 1.73 x Down regulated 3.0 -1.00 0.317 
IRS1 5.42 x Up regulated 0.0 -2.00 0.046 
SLC2A4RG 7.63 x Up regulated 0.0 -2.00 0.046 
Table 12: Relative quantification of IUGR juvenile macaques gene expression against 
control juvenile macaques. Highlighted rows indicate p < 0.05 
 
3.2.5 Association of biochemical parameters with metabolic gene expression level: 
juvenile macaques at 15 months 
Spearman's rank correlation coefficient was used to look for association between 
biochemical parameters, morphometrics and muscle gene expression levels in 15 months 
juvenile macaques. 3 genes had significant correlations with IVGTT k-value: MSTN had 
a negative correlation (ρ = -0.810, p = 0.015) (figure 14A) and IRS1 and SLC2A4RG had 
positive correlations (ρ = 0.881 and 0.762 respectively, p < 0.05) (figure 14B and 14C). 
AKT1 was positively associated with fasting glucose (ρ = 0.732, p = 0.039) (figure 14D). 
No significant associations were observed for fasting insulin, lipid panel tests, insulin 
resistance and sensitively indexes. (p > 0.05)      
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Figure 13: Graphic representation of relative quantification of IUGR juvenile macaques 
gene expression against control juvenile macaques. Error bars denote range. * indicates p 
< 0.05. 
 
3.2.6 Physical and biochemical properties analysis: juvenile macaques at 24 months 
(9 months after diet treatment) 
At the time of data collection, 25 juvenile macaques had undergone diet treatment that 
consisted of standard lab diet or high fat obesity diet. Out of the 25, 9 control and 9 IUGR 
macaques had reached 9 months of diet treatment, on which measurements and muscle 
biopsies were taken.  
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Figure 14: 15 months juveniles macaque scatterplots and linear trendline. A: MSTN 
expression level against k-value, B: IRS1 expression level against k-value, C: 
SLC2A4RG expression level against k-value, D: AKT1 expression level against fasting 
glucose. Strenght of correlationship, ρ, and the p value are stated on the top right of the 
plot. 
 
For the 18 juvenile macaques, the grouping and the number of subjects were as follows: 
1. Control & standard diet (C-S): n = 3 
2. Control & high fat diet (C-H): n = 6 
3. IUGR & standard diet (I-S): n = 3 
4. IUGR & high fat diet (I-H): n = 6 
As the distribution of this set of data is highly skewed, median and range were reported 
instead, Kruskal-Wallis one-way ANOVA was used to check on any differences among 
the 4 groups, followed by 4 Mann–Whitney U tests to access any difference between 1) 
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C-S and C-H, 2) C-S and I-S, 3) C-H and I-H, 4) I-S and I-H. Differences between C-H 
and I-S & C-S and I-H were not looked into, as their results were not meaningful for the 
study.  
Kruskal-Wallis analysis showed total cholesterol and HDL having significant differences 
among the 4 groups (p < 0.05) (table 13). Further analysis using multiple Mann–Whitney 
U tests indicated significant differences only between I-S and I-H & between C-S and C-
H for both total cholesterol and HDL (U = 0.0, Z = -2.32, p =0.020) (figure 15A), with 
the high fat diet group having more cholesterol and HDL than standard diet groups . In 
addition, I-S were significantly shorter in CRL than C-S (U = 0.0, Z = -1.96, p =0.050) 
(figure 17C), and I-S were significantly lighter in weight as compared to I-H (U = 1.0, Z 
= -2.07, p =0.039) (figure 15B). There were no significant differences for BMI, IVGTT 
k-value, triglyceride, LDL, fasting glucose and insulin, as well as insulin resistance and 
sensitively indexes among all 4 groups (p > 0.05). 
3.2.7 Metabolic gene expression analysis: juvenile macaques at 24 months  
RNA extracted from all 18 muscle tissues achieved RIN of 5.4 to 8.2, which were 
acceptable for cDNA synthesis and real time PCR analysis. During the calculation of the 
gene expression analysis shown in table 14 and figure 16, normalization against the 
geometric mean of three housekeeping genes, GAPDH, BACT and RPL13a, were done 
and RQ of each gene expression level was calculated using C-S group as a reference 
group (RQ = 1.0) . Kruskal-Wallis one-way ANOVA was used to check on any 
differences among 4 groups in gene expression level, followed by 4 Mann–Whitney U 
tests to access any differences between 1) C-S and C-H, 2) C-S and I-S, 3) C-H and I-H, 
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4) I-S and I-H. Differences between C-H and I-S & C-S and I-H in gene expression were 
not investigated, as their results were not meaningful for this study.  
Kruskal-Wallis test showed no significant differences among the 4 groups in the 
expression levels of all 19 genes (table 14). However, multiple Mann-Whitney U 
comparison found some groups having significant differential expression levels in 6 
genes (p < 0.05, table 14 & figure 16A), and listed as follows: 
1. SLC2A4: C-S had 2.1 fold decrease compared to C-H (Z = -2.32, p = 0.020) 
2. IRS2: C-H had 2.5 fold decrease compared to I-H (Z = -2.08, p = 0.037) 
3. MEF2A: C-S had 1.5 fold decrease compared to I-S (Z = -1.96, p = 0.050) 
4. HK2: C-S had 1.8 fold increase compared to C-H (Z = -2.32, p = 0.020) 
5. MSTN: C-S had 3.9 fold decrease compared to C-H (Z = -2.07, p = 0.039) 
6. C-S had 4.9 fold decrease compared to I-S (Z = -1.96, p = 0.050) 
7. PIK3R1: C-S had 2.1 fold increase compared to I-S (Z = -1.96, p = 0.050) 
No significant differences was observed for the other 13 genes in multiple comparison 
tests (p > 0.05, figure 16B & 17) 
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Parameters at 24 
months old 
C-S 
(n = 3) 
C-H 
(n = 6) 
I-S 
(n = 3) 
I-H 
(n = 6) 
Kruskal-Wallis 
p value 
Weight (kg) 2.08 (1.65-2.42) 1.88 (1.58-2.38) 1.39 (1.24-1.71) 1.96 (1.71-2.11) 0.126 
CRL (cm) 31.0 (29.3-32.3) 31.6 (29.0-33.8) 28.4 (26.8-28.8) 30.8 (27.0-32.0) 0.076 
BMI (kg/m
2
) 19.9 (19.2-25.2) 19.3 (16.6-22.5) 19.3 (14.9-21.1) 21.6 (17.2-23.4) 0.409 
IVGTT 
k-value 
5.39 (5.09-6.13) 5.50 (2.32-7.32) 5.49 (4.82-5.84) 5.23 (3.01-7.67) 0.825 
Fasting glucose 
(mmol/L) 
2.40 (2.20-3.70) 3.20 (2.30-4.20) 2.60 (2.10-3.40) 2.70 (1.90-4.10) 0.706 
Fasting insulin 
(mU/L) 
26.5 (14.8-28.5) 19.2 (4.60-84.1) 15.7 (4.10-50.2) 40.1 (16.6-66.2) 0.402 
Total cholesterol 
(mmol/L) 
2.85 (2.36-2.95) 4.79 (3.94-5.88) 2.94 (1.86-2.97) 4.90 (3.25-7.50) 0.010 
Triglycerides 
(mmol/L) 
0.37 (0.20-0.42) 0.39 (0.17-0.82) 0.31 (0.30-0.34) 0.39 (0.17-0.51) 0.835 
HDL (mmol/L) 1.37 (1.29-1.60) 2.30 (1.94-3.00) 1.16 (1.15-1.28) 2.06 (1.56-2.81) 0.007 
LDL (mmol/L) 1.32 (1.04-2.12) 2.13 (0.66-3.33) 1.52 (0.56-1.67) 2.23 (0.70-5.33) 0.337 
HOMA-IR 3.04 (1.45-4.36) 2.60 (0.63-13.8) 1.47 (0.47-7.59) 5.94 (1.42-7.80) 0.691 
QUICKI 0.32 (0.31-0.36) 0.33 (0.27-0.42) 0.36 (0.29-0.44) 0.30 (0.29-0.36) 0.679 
Table 13: Juvenile macaques’ morphometric and biochemical parameters at 24 months old, 9 months after diet treatment. 
Values presented are in the format of median (min-max). Highlighted rows indicate p < 0.05 
45 | P a g e  
 
 
Figure 15: Graphic repersentation of Juvenile macaques’ morphometric and biochemical 
parameters at 24 months old, 9 months after diet treatment. Error bars denote range. * 
beside parameter at x-axis indicates p ≤ 0.05 by Kruskal-Wallis test. * on top between 2 
bar indicates p ≤ 0.05 by Mann–Whitney U test between 2 groups.
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3.2.8 Association of biochemical parameters with metabolic gene expression level: 
juvenile macaques at 24 months 
Spearman's rank correlation coefficient was used to look for association between 
biochemical morphometrics and muscle gene expression level in 24 months juvenile 
macaques. 2 significant associations were observed: IVGTT k-value was negatively 
correlated with MEF2A (ρ = -0.569, p = 0.014) (figure 18A) and fasting glucose was 
negatively correlated with PKM2 (ρ = -0.529, p = 0.024) (figure 18B). No significant 
associations was observed for fasting insulin, lipid panel tests, insulin resistance and 
sensitively indexes (p > 0.05). 
3.3 Adult cynomolgus macaque IGT model 
3.3.1 Morphometric analysis: adult macaques 
Table 15 shows the summary for the macaques’ morphometrics, before and after diet 
treatment. Mann-Whitney U test was used for statistical analysis. Before diet treatment, 
all 14 adults have an average weight of 6.95 ± 0.95kg and an average BMI of 13.62 ± 
1.06kg/m
2
. After six month high fat diet, IGT macaques had a significant 64% weight 
gain as compared to the weight before high fat treatment (Z = -3.130, p = 0.002). Also, 
IGT macaques were 54% higher on BMI as compared to the BMI before high fat 
treatment and this difference is significant (Z = -3.134, p = 0.002). No significant 
difference was observed in CHL between the two groups (Z = -1.670, p = 0.095). 
3.3.2 Biochemical analysis: adult macaques 
Table 16 illustrates the macaques’ biochemical parameters before and after diet treatment. 
Mann-Whitney U test was used for statistical analysis. From the analysis, IVGTT k-value, 
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Figure 16: Graphic representation of relative quantification of SLC2A4, IRS2, MEF2A, 
HK2, MSTN, PIK3R1, INSR, GCK, PKM2, GYS1, AKT1 and AKT2 in C-H, I-S and I-
H juvenile macaques against C-S juvenile macaques as reference group, with significant 
differences in A. Error bars denote range. * on top between 2 bar indicates p ≤ 0.05 by 
Mann–Whitney U test between 2 groups 
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Figure 17: Graphic representation of relative quantification of PIKC3a, PIK2Cb, PDPK1, 
GSK3b, FOXO1, IRS1 and SLC2A4RG in C-H, I-S and I-H juvenile macaques, against 
C-S juvenile macaques as reference group. Error bars denote range.  
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Gene Group RQ 
Kruskal-Wallis 
p value 









C-S C-H -2.32 0.020 
C-H 2.127 C-S I-S -1.09 0.275 
I-S 1.581 C-H I-H -0.80 0.423 




C-S C-H -1.29 0.197 
C-H 1.436 C-S I-S -0.22 0.827 
I-S 1.168 C-H I-H -0.32 0.749 




C-S C-H -0.52 0.606 
C-H 0.752 C-S I-S -1.53 0.127 
I-S 0.410 C-H I-H -0.48 0.631 




C-S C-H -1.03 0.302 
C-H 1.588 C-S I-S -0.22 0.827 
I-S 1.255 C-H I-H -2.08 0.037 




C-S C-H -0.26 0.796 
C-H 1.004 C-S I-S -1.97 0.050 
I-S 0.674 C-H I-H -0.64 0.522 




C-S C-H -0.26 0.796 
C-H 0.968 C-S I-S -0.66 0.513 
I-S 1.542 C-H I-H -1.28 0.200 




C-S C-H -1.81 0.071 
C-H 1.714 C-S I-S -0.22 0.827 
I-S 1.037 C-H I-H -0.32 0.749 




C-S C-H -2.32 0.020 
C-H 1.828 C-S I-S -1.09 0.275 
I-S 1.674 C-H I-H -1.44 0.150 
I-H 2.745 I-S I-H -1.03 0.302 
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Gene Group RQ 
Kruskal-Wallis 
p value 









C-S C-H -0.78 0.439 
C-H 1.143 C-S I-S -0.22 0.827 
I-S 0.976 C-H I-H 0.00 1.000 




C-S C-H -0.26 0.796 
C-H 0.993 C-S I-S -0.22 0.827 
I-S 0.985 C-H I-H -0.64 0.522 




C-S C-H -2.07 0.039 
C-H 0.255 C-S I-S -1.97 0.050 
I-S 0.204 C-H I-H -0.32 0.749 




C-S C-H -0.52 0.606 
C-H 1.157 C-S I-S -0.22 0.827 
I-S 0.941 C-H I-H -1.44 0.150 




C-S C-H -0.26 0.796 
C-H 1.180 C-S I-S -0.22 0.827 
I-S 1.313 C-H I-H -0.64 0.522 




C-S C-H -0.78 0.439 
C-H 1.193 C-S I-S -1.96 0.050 
I-S 2.089 C-H I-H -0.48 0.631 




C-S C-H -1.03 0.302 
C-H 1.392 C-S I-S -1.09 0.275 
I-S 1.318 C-H I-H -0.80 0.423 




C-S C-H -0.52 0.606 
C-H 1.047 C-S I-S -1.09 0.275 
I-S 0.715 C-H I-H -0.32 0.749 
I-H 0.967 I-S I-H -1.03 0.302 
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Gene Group RQ 
Kruskal-Wallis 
p value 









C-S C-H 0.00 1.000 
C-H 1.185 C-S I-S -1.53 0.127 
I-S 1.259 C-H I-H 0.00 1.000 




C-S C-H -1.29 0.197 
C-H 3.046 C-S I-S -1.53 0.127 
I-S 6.767 C-H I-H -1.44 0.150 





C-S C-H -1.29 0.197 
C-H 4.660 C-S I-S -1.09 0.275 
I-S 9.345 C-H I-H -0.64 0.522 
I-H 10.909 I-S I-H -0.26 0.796 
Table 14: Relative quantification of C-H, I-S and I-H juvenile macaques gene expression 
against C-C-S juvenile macaques as reference group. Kruskal-Wallis test was deployed 
for comparison across 4 groups, followed by 4 set of Mann-Whitney U test between 2 





Figure 18: 24 months juveniles macaques scatterplots and linear trendline. A: MEF2A 
expression level against k-value, B: PKM2 expression level against fasting glucose. 








Before treatment After treatment Mann–Whitney U test  
(2-tailed) 
NGT 
(n = 7) 
IGT 
(n = 7) 
NGT 
(n = 7) 
IGT 
(n = 7) 
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0.0 -3.134 0.002 
Table 15: Adult macaques’ morphometric before and after diet treatment. Values 
presented are in the format of mean (SD). Highlighted rows indicate p < 0.05.  
 
fasting insulin, HOMA-IR and QUICKI exhibited significant differences between NGT 
and IGT macaques (p < 0.05). IGT macaques had a 22% decrease in IVGTT k-value (Z = 
-2.108, p = 0.035), 5.2 times increase in fasting insulin value (t = Z = -3.130, p = 0.001), 
5.8 times increase in insulin resistance index HOMA-IR (Z = -3.130, p = 0.002) and a 23% 
decrease in insulin sensitivity index QUICKI (Z = -3.090, p = 0.002). No significant 
differences were observed in the fasting glucose and the lipid panel tests between both 
groups (p > 0.05). 
3.3.3 Metabolic gene expression analysis: adult macaques 
All RNA extracted from muscle tissue achieved RNA integrity number (RIN) of 5.5 to 
8.0, stating that they were suitable for cDNA synthesis and real time PCR analysis. 
During the calculation of the gene expression analysis, normalization against the 
geometric mean of three housekeeping genes, GAPDH, BACT and RPL13a, were done 
and RQ of each gene expression level was calculated using NGT group as a reference 
group. 
Table 17 shows the magnitude and direction of muscle gene regulation in IGT macaques. 
Any changes less than 10% (< 1.10 fold) were not considered as the observed value can 




Before treatment After treatment Mann–Whitney U test  
(2-tailed) 
NGT 
(n = 7) 
IGT 
(n = 7) 
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(n = 7) 
IGT 
(n = 7) 
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0.0 -3.090 0.002 
Table 16: Adult macaques’ biochemical parameters before and after diet treatment. 
Values presented are in the format of mean (SD). Highlighted rows indicate p < 0.05.  
 
be due to chance and experimental error. Mann-Whitney U test was used to access any 
significant differences in the regulation observed. Figure 19 illustrates the regulation of 
muscle gene expression level in a bar graph. 
It was observed that 4 genes were down regulated with a magnitude of 1.1 fold to 2.8 fold, 
whereas 13 genes were up regulated with similar magnitude. Out of these 13 up regulated 
genes, AKT1 and AKT2 expression level were significantly up regulated in IGT 
macaques by 1.36 fold and 1.29 fold respectively (p < 0.05). Also IRS1 expression level 
was significantly down regulated in IGT macaque by 2.29 fold (Z = -1.981, p = 0.048). 
GCK and IRS2 were not regulated and there were no significant differences in the 
54 | P a g e  
 
remaining 14 gene expression level, although some genes like SLC2A4RG exhibited a 
larger decrease in expression level in IGT macaques (2.79 fold, p > 0.05).  
Gene Relative quantification of IGT 
(NGT as reference) 
Mann–Whitney U test  
(2-tailed) 
Magnitude Direction  U Z p  
SLC2A4 1.12 x Down regulated 20.0 -0.575 0.562 
INSR 1.22 x Up regulated 14.0 -1.342 0.180 
GCK 1.08 x No Change 24.0 -0.064 0.949 
IRS2 1.01 x No Change 24.0 -0.064 0.949 
MEF2A 1.33 x Up regulated 14.0 -1.342 0.180 
PKM2 1.25 x Up regulated 17.0 -0.958 0.338 
GYS1 1.17 x Up regulated 16.0 -1.086 0.277 
HK2 1.14 x Up regulated 24.0 -0.064 0.949 
AKT1 1.36 x Up regulated 8.0 -2.108 0.035 
AKT2 1.29 x Up regulated 6.0 -2.364 0.018 
MSTN 1.40 x Up regulated 10.0 -1.853 0.064 
PIK3Ca 1.15 x Up regulated 17.0 -0.958 0.338 
PIK3Cb 1.22 x Up regulated 16.0 -1.086 0.227 
PIK3R1 1.51 x Up regulated 14.0 -1.342 0.180 
PDPK1 1.26 x Down regulated 13.0 -1.469 0.142 
GSK3b 1.39 x Up regulated 12.0 -1.597 0.110 
FOXO1 1.66 x Up regulated 10.0 -1.853 0.064 
IRS1 2.29 x Down regulated 9.0 -1.981 0.048 
SLC2A4RG 2.79 x Down regulated 15.0 -1.214 0.225 
Table 17: Relative quantification of IGT macaques gene expression against NGT 
macaques.  Highlighted rows indicate p < 0.05 
 
3.3.4 Association of biochemical parameters with metabolic gene expression level: 
adult macaques  
Using Spearman's rank correlation coefficient to check for association between 
biochemical morphometrics and muscle gene expression level, there were a number of 
significant associations observed. IVGTT k-value was negatively correlated with AKT2 
expression level (ρ = -0.564, p = 0.036, figure 20A). Next, Fasting glucose value was 
negatively correlated with IRS2 expression level (ρ = -0.557, p = 0.039, figure 20B). 
Fasting insulin value was positively associated with AKT1 expression level (ρ = 0.617,  
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Figure 19: Graphic representation of relative quantification of IGT macaques gene 
expression against NGT macaques. Error bars denote SD. * indicates p < 0.05, ** 
indicates p < 0.01  
 
 
p = 0.019, figure 20C) and MSTN expression level (ρ = 0.600, p = 0.023, figure 20D), 
whereas the same parameter is negatively correlated with SLC2A4RG expression level (ρ 
= -0.641, p = 0.014, figure 20E). Interestingly, insulin resistance index HOMA-IR shared 
similar relationships with AKT1, MSTN and SLC2A4RG as what fasting insulin had, 
with slight difference in the strength of association (ρ = 0.596, ρ = 0.643 and ρ = -0.647 
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respectively, p < 0.05, figure 20F-20H). There were no significant associations observed 
with the lipid panel tests and insulin sensitivity index QUICKI against any gene 
expression levels (p > 0.05)  
 
Figure 20: Adult macaques scatterplots and linear trendline. A: AKT2 expression level 
against k-value, B: IRS2 expression level against k-value, C: AKT1 expression level 
against fasting insulin, D: MSTN expression level against fasting insulin, E: SLC2A4RG 
expression level against fasting insulin, F:  AKT1 expression level against HOMA-IR, G: 
MSTN expression level against HOMA-IR, H: SLC2A4RG expression level against 
HOMA-IR. Strength of correlationship, ρ, and the p value are stated on the top right of 
the plot.   
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CHAPTER 4 DISCUSSIONS 
4.1 Primer validated for all gene expression studies in cynomologus macaque 
One of the core objectives of these studies is to look at metabolic gene expression levels 
in cynomolgus macaque. Due to a lack of cynomolgus macaque’s sequence information 
in any genetic sequence database at the point of work, in house primer design based on 
human and rhesus macaque sequences were necessary. As human, rhesus and 
cynomolgus macaques share more than 90% identity in sequence, designing primers that 
flank the conserved region of the gene of interest in both human and rhesus macaque 
would have a higher chance of success when using them to amplify cynomolgus macaque 
genes. All sets of primers yielded a single product of the expected sizes. Furthermore, the 
sequence of PCR products indicated at least 95% homology with the source of the genetic 
sequences used to design primer. In addition to the recent release of cynomolgus 
macaque genome, BLAST results of primers and PCR products displayed at least 90% 
and 95% homology respectively, confirming that all the primers were amplifying the 
intended genes of interest and their locus. Hence they were validated to be used in real 
time PCR for gene expression studies. All primers had an efficiency of at least 90%, 
fitting the criteria of deploying comparative CT method to normalize gene of interest 
with housekeeping genes to obtain Δct, then comparing the control group to obtain ΔΔct, 
and lastly using 2
-ΔΔct
 to calculate the fold change (in RQ).   
4.2 Nutrition-mediated IUGR macaque were born lighter and experienced ‘catch-up 
growth’ 
Our first objective for this study is to investigate any differences between normal and  
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nutrition-mediated IUGR infant macaque in their weight and body length for their first 9 
months of life. After birth, it was found that IUGR neonates were 10% lighter than 
control neonates and this finding was significant by Mann–Whitney U test. Our 
observations were consistent with the literature presented on growth restricted neonates 
having LBW in animal models, as well as in human. On average, the BMI of IUGR 
neonates was 10% lower, but this was not significant by Mann–Whitney U test. Despite 
lower birth weight, IUGR neonates had similar body length as compared to the control 
neonates. Although the definition of IUGR is associated with LBW and SGA, there were 
rodent models in which no significant differences in the body size of IUGR pups were 
observed as compared to the normal pups (Schwartz et al, 1998; Simmons et al, 2001; 
Coupe et al, 2009). Nevertheless, LBW is still the main criteria for human IUGR 
offspring, which all validated IUGR animal models have reflected, and we have achieved 
this criteria too. Hence we can conclude that our nonhuman primate IUGR model is valid.             
Physical morphometric measures for both control and IUGR cohort at 3 months to 9 
months were similar throughout. However an analysis on the changes of these physical 
morphometrics in a 3 month period indicated a significant change in BMI in IUGR cohort 
from birth to 3 months old as compared to control cohort. This was attributed to the 
larger weight gain in IUGR infant macaques than the control infant macaques, but that 
observation was not significant by Mann–Whitney U test. From this analysis, it we 
demonstrated that IUGR infant macaques experienced “catch-up growth” during the first 
3 months of their life. This phenomenon was also observed in other IUGR rodent models 
with the hypothesis that IUGR subjects accelerated in growth to match with their peers, 
but at a disadvantage in later life with early onset of metabolic disease (Coupe et al, 2009; 
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Shahkhalili et al 2010). The changes in weight, CRL and BMI were almost similar for 
both cohorts from 3 to 6 months and 6 to 9 months, stating that both cohorts were 
growing at the similar rate.  
4.3 Higher glucose clearance rate, total cholesterol and triglycerides observed in 
IUGR juvenile macaques at 15 months 
Biochemical parameters of both cohorts showed that IUGR macaques had a higher 
glucose clearance rate, total cholesterol and triglycerides at 15 months old. All these 
findings were significant by Mann–Whitney U test (p < 0.05). From this, we 
hypothesized that the observed differences could be the fetal programming in utero. As 
IUGR infants need to “catch-up” with their normal peer, their overall metabolism 
increases in order to gain weight and build. Hence glucose uptake is increased, which 
explains the fast glucose clearance rate from the blood. Also, lipid metabolism is 
accelerated to create an alternate energy source should glucose not be available (a 
condition which was likely to happen in utero during nutrition restriction of mothers). 
This survival response increases the production and absorption of fats, which causes an 
increase in plasma lipid levels in IUGR juveniles macaques, 90% increase in total 
cholesterol and triglycerides and 20% increase in HDL and LDL cholesterol.  
4.4 Accelerated insulin-glucose signaling observed in IUGR juvenile macaques 
We are interested to find any differences in gene expression level between both groups at 
15 months. Real time PCR analysis and Mann–Whitney U test showed AKT2 was 
significantly down regulated , and PIK3R1, IRS1 and SLC2A4RG were significantly up 
regulated in muscle tissue of IUGR juvenile macaques (p < 0.05). These observations 
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were opposite of the gene expression in IGT adult macaques earlier in section 4.2, 
suggesting that insulin and glucose signaling pathways were accelerated. Even though the 
following differences were not significant by Mann–Whitney U test, IUGR juvenile 
macaques had a lower HOMA-IR and higher QUICKI as control group (p > 0.05), 
suggesting that they were more insulin sensitive. Also, myostatin expression level was 
decreased in IUGR juvenile macaques, suggesting that muscle differentiation, growth and 
associated metabolism were encouraged. All the results derived from gene expression 
analysis indicated that cellular insulin and glucose metabolism in muscle tissue was 
elevated, which support the phenotype observed in the biochemical results of IUGR 
juvenile macaques.  
High glucose clearance and insulin sensitivity persisted in 24 months old IUGR juvenile 
macaques when comparing C-S against I-S. Also, the regulations of AKT, IRS, 
SLC2A4RG, PIK3R1 and MSTN in muscle tissues were of the same pattern as the 
observations made at the 15 months analysis, but only IRS2, PIK3R1 and MSTN were 
significant (p < 0.05). These observations hint that fast insulin and glucose metabolism 
continues for the past nine months.  
4.5 Faster deterioration of insulin-glucose signaling in IUGR juvenile macaques 
compared to control juvenile macaques exposed to a high fat diet  
We are interested to investigate any changes in biochemical and physical morphometrics, 
as well as expression levels of 19 metabolic genes, after 9 months of diet treatment. 
Comparing C-S against C-H and I-S against I-H, macaques in high fat diet groups had 
increased plasma lipid levels with total cholesterol and HDL having significance (p < 
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0.05). Looking at the changes between these two pairs, IUGR juvenile macaques had 
significant weight gain after high fat diet treatment (p < 0.05), whereas control juvenile 
macaques had a similar weight before and after high fat diet treatment. Interestingly, 
control juvenile macaques had slightly better insulin sensitivity after high fat diet, based 
on IVGTT, HOMA-IR, QUICKI and gene expression data, whereas IUGR juvenile 
macaques were more insulin resistant after high fat diet. However, these data were not 
statistically significant at this point of time. These seem to suggest that insulin 
metabolism might be greatly altered in IUGR juvenile macaques and leads towards IGT 
after a 9 months high fat diet challenge. On the other hand, the insulin and glucose 
metabolism of control juvenile macaques under high fat diet started to accelerate similar 
to the observations made in IUGR macaques at 15 months. Viewing the high fat diet as 
an environmental stimulus of an unhealthy lifestyle, we theorized that IUGR subjects are 
programmed to accelerate overall metabolism in order to adapt to a nutrient-deprived 
environment, but this developmental trade-off that they have made and the exposure to an 
unhealthy lifestyle predisposes them to metabolic disease at an earlier stage of life. This 
could be due to the prolonged stimulation of the insulin-glucose pathway and when the 
ability of the pathway to adapt to the stimulus is exceeded, this leads to pathology and 
disease.  
Gene expression data showed significant up regulation of HK2, IRS2, and SLC2A4, and 
down regulation of MSTN in C-H as compared to C-S (p < 0.05). These observations are 
similar to 15 months juvenile macaques with elevated insulin and glucose metabolism in 
relation to mRNA expression level mentioned in section 4.6. There were no significant 
differences in all gene expression data between I-S and I-H (p > 0.05). 
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4.6 Adult cynomolgus macaque IGT model established and validated 
An objective in this study is to establish an adult nonhuman primate diabetic model using 
cynomolgus macaques. From our study, macaques fed with 35% high fat diet for six 
months significantly gained about 5kg (64%) in weight as compared to those continued 
on standard lab diet (p < 0.05). IGT macaques were physically larger than normal 
macaques in the NGT group, with little or no change in their length from head to heel 
(figure 21). Thus, IGT macaques gained about 8kg/m
2
 in their BMI, to an average of 
21.3kg/m
2
, 54% increase as compared to NGT macaques which had an average BMI of 
13.3kg/m
2
. This indicated that the high fat diet used was effective in generating obese 
macaques.  
To test for diabetes, insulin resistance and sensitivity, IVGTT and measurement for 
fasting glucose and insulin were deployed. Using the cut-off proposed by Amatuzio et al, 
 
Figure 21: Photos of adult macaques involved in prediabetes study. Left: macaque in IGT 
group. Right: macaque in NGT group    
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1953 for human, a mean k-value of more than 3 is considered normal glucose tolerance; a 
mean k-value between 2.0 to 3.0 is considered IGT; a mean k-value between 1.5 to 2.0 is 
considered mild diabetes, and a mean k-value less than 1.5 is considered severe diabetes. 
Results of IVGTT showed that IGT macaques had a k-value of less than 3.0, 
demonstrating macaques having impaired glucose tolerance. The control group displayed 
normal glucose clearance rate with k-value of more than 3.0. Elevated fasting blood 
glucose was observed in IGT macaques but this was not significant and the values were 
within the normal range of less than 6.0 mmol/L. This was expected as normal glycemic 
control is maintained prior to the progression to T2DM, from normal to IGT state. In 
addition, fasting blood insulin in IGT macaques were significantly raised by 5 fold as 
compared to control group. Also using fasting glucose and insulin values, insulin indexes 
HOMA-IR and QUICKI were calculated. These 2 indexes had shown high correlation 
and reliability with the gold standard hyperinsulinemic euglycemic clamp (Yokoyama et 
al, 2004), whereby the latter is complicated and time consuming to perform. From the 
calculations, IGT macaques were over 7.0 in HOMA-IR and under 0.30 for QUICKI, 
revealing signs of insulin resistance and insensitivity in IGT macaques. All these signs 
are similar to macaque models by Cefalu WT, 2000 and Bodkin, 2000, indicating early 
T2DM progression. Such observations validated our nonhuman primate IGT model.  
Lipid panel tests showed IGT macaques on average had a slight increase in total 
cholesterol, triglycerides, HDL and LDL, due to higher fat intake. However such 
increments observed as compared to control group were not significant and still within 
the normal range, confirming that the animals were not suffering from hyperlipidemia, a 
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condition which may complicate our study on metabolic gene expression level in an IGT 
subject.  
4.7 Deterioration of insulin-glucose signaling observed in IGT macaque  
The next objective is to characterize mRNA expression of genes involved in insulin and 
glucose metabolism and check for any differences between normal and IGT macaques. 
IRS1 expression level was decreased by 2.3 fold in muscle of IGT macaques and it was 
significant by Mann–Whitney U test (p < 0.05). In addition, IRS2 expression level was 
shown to have significant negative correlation with fasting blood glucose (p < 0.05). 
These observations are consistent with other studies on IRS expression level in insulin 
resistant cell lines and diabetic models. As IRS regulate the insulin signaling pathway at 
the beginning by relaying insulin signals from the receptor to intracellular effectors, a 
reduction in IRS will slow down the downstream signaling pathway, which leads to a 
reduced sensitivity in response to glucose regulation. In response to insulin signaling 
down regulation after IRS, insulin receptor production was observed to increase to 
compensate for the reduced sensitivity (a negative feedback loop in muscle insulin 
signaling pathway). This was shown by an up regulation of INSR by 1.2 fold in muscle 
tissue of IGT macaques, but unfortunately such differences were not significant by 
Mann–Whitney U test (p > 0.05), probably due to a small sample size.           
On the other hand, AKT1 and AKT2 were found to be up regulated in muscle tissue of 
IGT macaques. As the role of AKT and phosphorylated AKT are well established in 
glucose transport and downstream signaling of insulin-glucose pathway, we hypothesized 
that by up regulating AKT1 and AKT2, more kinases are available to be activated via 
65 | P a g e  
 
phosphorylated, and bring the insulin signaling back to normal level, after the pathway 
has slowed down because of reduced IRS1. Also, more kinases are available trying to 
compensate the reduced activity of AKT1 and AKT2 due to reduced PDPK1 activation. 
Furthermore, AKT1 expression level was positively associated with fasting blood insulin 
and HOMA-IR (p < 0.05), reinforcing our hypothesis on up regulation of AKT in insulin 
resistant tissue.   
Next, we observed a decrease in SLC2A4RG expression level in muscle tissue of IGT 
macaques. Although this was not significant by Mann–Whitney U test (p > 0.05), 
associations between fasting blood insulin and HOMA-IR were significant by Pearson 
correlation coefficient (p < 0.05). Such correlation translates to a lower SLC2A4RG 
expression level when fasting blood insulin and HOMA-IR increases. These observations 
are similar to other studies on glucose transporter 4 and its regulatory gene, whereby a 
decrease in SLC2A4RG will decrease SLC2A4 expression, hence leading to lower 
glucose transporter 4 proteins on the membrane to facilitate glucose uptake. Expression 
levels of SLC2A4 in muscle tissue of IGT macaques were slightly reduced, but this was 
not significant by Mann–Whitney U test (p > 0.05), probably due to a small sample size. 
Such reduction will lead to a decreased insulin sensitivity and increased insulin resistance  
Lastly, myostatin expression was found to be increased in muscle tissues of IGT 
macaques. This finding was not significant by Mann–Whitney U test (p > 0.05), but 
associations between fasting blood insulin and HOMA-IR were significant by Pearson 
correlation coefficient (p < 0.05). This result is similar to a study done by Hittel at el, 
2009, whereby increased secretion and expression of myostatin was found in muscle 
tissue of obese subjects with higher BMI and HOMA-IR than the lean subjects. As a 
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negative regulator of muscle differentiation and growth belonging to a member of the 
TGF beta protein family, myostatin was predicted to have involvement in insulin and 
glucose metabolism after studies showed hypermuscular myostatin null mice had reduced 
fat mass and were spared from dietary-induced insulin resistance after diet treatment 
(Zhao et al, 2005; Feldman et al, 2006). To date, the cellular mechanism of myostatin 
regulating insulin and glucose metabolism has not established. However we speculated 
that the reduced insulin- glucose signaling causes myostatin expression level to be up 
regulated. This condition is similar to that of starving muscle whereby little glucose is 
available and the oxidative catabolism of lipid is reduced or incomplete when such 
alternative energy source is used (Pender at el, 2005).  
To summarize, down regulation of IRS1, SLC2A4RG and up regulation of MSTN, 
AKT1, AKT2 were seen in IGT adult macaques. The expression profiles of these five 
genes were found to be altered as they are slowly progressing toward IGT.      
4.8 Similar gene expression of AKT1, AKT2 and IRS1 between IUGR juvenile 
macaques and adult IGT macaques - the transition point from insulin sensitive to 
insulin resistance 
A direct comparison in the insulin-glucose biochemical data and the gene expression data 
between IUGR high fat (I-H) juvenile macaques and IGT adult macaques (table 18) 
shows that I-H juvenile macaques are better in glucose clearance and sensitivity, and 
have a faster insulin-glucose signaling as compare to IGT adult macaques. However 
taking a closer look at AKT1, MEF2A, GSK3b and IRS1 expression levels, we observed 
a similar pattern as what was observed in IGT adult macaques, but with a smaller 
67 | P a g e  
 
magnitude. This observation may indicate a transition point from being insulin sensitive 
to developing insulin resistance. With all these observations, figure 22 depicts the 
hypotheses proposed in this chapter: IUGR subjects programmed to have insulin-glucose 
signaling accelerated in order to achieve an elevated growth rate to match its normal 
peers, but the animals deteriorate earlier with unhealthy diet due to exhaustion of the 
body’s ability to adapt.  




IVGTT  k-value 5.23 2.91 
Fasting glucose (mmol/L) 2.70 3.47 
Fasting insulin (mU/L) 40.1 94.1 
HOMA-IR 5.94 14.61 
QUICKI 0.30 0.27 
Gene RQ 
SLC2A4 1.506 0.891 
INSR 1.058 1.223 
GCK 1.554 1.081 
IRS2 3.087 1.010 
MEF2A 1.254 1.334 
PKM2 1.056 1.257 
GYS1 1.600 1.167 
HK2 1.647 1.142 
AKT1 1.204 1.361 
AKT2 1.077 1.290 
MSTN 0.900 1.404 
PIK3Ca 1.077 1.146 
PIK3Cb 0.948 1.218 
PIK3R1 0.769 1.506 
PDPK1 0.932 0.796 
GSK3b 1.352 1.386 
FOXO1 0.801 1.659 
IRS1 0.696 0.436 
SLC2A4RG 1.167 0.359 
Table 18: A direct comparison in the insulin-glucose biochemical data and the gene 
expression data between IUGR high fat juvenile macaques and IGT adult macaques 
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Figure 22: A schematic diagram of the hypothesis on accelerated insulin-glucose 
signaling and early development of metabolic disease in IUGR subject. Blue region 
represents hyper-sensitive signaling, white region represents normal sensitivity, red 
region represents slow signaling and insulin resistance. Red line shows the trend of an 
IUGR offspring and blue line shows the trend of a normal offspring      
 
4.9 Strengths and limitations of these studies 
Although there have been many studies on the effect of IUGR on metabolic disease in 
later life, these were not done on a nonhuman primate model. The strength of using a 
nonhuman primate model is that they share many similarities in reproductive physiology 
and disease progression with humans, In addition, interventional studies and sequential 
tissue samples collection are not feasible in human, but are possible in nonhuman primate. 
The findings in this thesis can be useful in translational research and screening of early-
onset T2DM in teenager and young adult, especially on those who were classified as 
IUGR after birth. Further research on AKT1, MEF2A, GSK3b and IRS1 can be done as 
they are potential molecular markers for diagnosing the transition point from insulin 
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sensitive to insulin resistance, whereby blood tests and OGTT cannot pick up the 
differences.     
This thesis does have its limitations. Due to logistic reasons, diet treatment is only 
possible for six months for adult macaques. It will be better if the high fat diet treatment 
for adult IGT macaques can last for nine months, such that the comparison between 
IUGR high fat juvenile macaques and IGT adult macaques will be more controlled and 
relevant. Also muscle biopsy and diet treatment of juvenile macaques at any time point 
before 15 months is not possible, as the work of this thesis was started when most of the 
juvenile macaques were reaching 18 months. Although most of the data were continuous 
variables, some of them exhibited a non-normal distribution and many of them had 
different variances (Levene's test p < 0.05), in which the assumption for parametric 
statistics is not valid. Hence parametric tests, such as student t-test and ANOVA, cannot 
be used for this thesis and statistical analysis were resorted to a more robust but less 
powerful non-parametric tests Mann–Whitney U test and Kruskal-Wallis test. As this is 
still an ongoing study, some of the analyses in this thesis are preliminary. Further works 
such as protein expression studies and epigenetic of the metabolic genes are required to 
validate our proposed hypotheses.  
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CHAPTER 5 CONCLUSION     
This thesis has established an IGT adult cynomolgus macaque model with higher BMI, 
elevated fasting insulin, increased insulin resistance and reduced glucose clearance which 
are consistent with other nonhuman primate diabetic models. IGT macaques displayed 
differential gene expression levels of down regulated IRS1, AKT1, AKT2 and 
SLC2A4RG, and up regulated MSTN. These are indicators of abnormal regulation of 
such genes in T2DM subjects.   
This thesis also argues in favor of the nutrient-mediated IUGR cynomolgus macaque 
model set up by us, in which IUGR neonates are lighter at birth and experience a catch-
up growth in the first 3 months of life, similar with other IUGR animal models. IUGR 
and control cohorts subsequently have similar growth patterns until 15 months. The 
IUGR group had accelerated insulin glucose metabolism and faster glucose clearance rate, 
with higher cholesterol and triglycerides as compared to the control. With a 9 months 
high fat diet treatment in place, IUGR juvenile macaques showed signs of deterioration in 
insulin glucose metabolism, with gene expression leading towards the profile observed in 
IGT adult macaques. On the other hand, control juvenile macaques on a high fat diet 
displayed up regulation of SLC2A4 and HK2, inferring faster glucose uptake and 
glycolysis. All these observations fit our hypothesis on distinctive features in metabolic 
gene expression levels, physical and biochemical characteristics between normal and IGT 
macaques, and between normal and IUGR offspring, with the refinement written as 
follows: IUGR subjects are programmed in utero to have accelerated insulin-glucose 
signaling in order to achieve an elevated growth rate to match its normal peers, but are 
more prone to deterioration at an earlier stage of life when exposed to unhealthy diet due 
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to exhaustion in insulin-glucose signaling cascade after the body has adapted to the 
accelerated pathway.  
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